Lilly, Innovent’s Tyvyt Registers Positive Outcomes in Esophageal and Gastric Cancer Trials
Innovent's innovative PD-1 inhibitor, Tyvyt (sintilimab), is a fully human IgG4 monoclonal antibody developed in collaboration with Eli Lilly. The immunotherapy is not FDA-approved yet. However, it has bagged regulatory approvals in China for three indications so far; relapsed/refractory classical Hodgkin lymphoma, non-squamous non-small cell lung cancer (nsqNSCLC), and recently for squamous NSCLC.
At the 2021 ESMO Annual Meeting, initial data were presented from two clinical trials evaluating sintilimab in combination with chemotherapy against two new cancer indications. Results from the Phase 3 ORIENT-15 and ORIENT-16 trials show that sintilimab plus chemotherapy significantly improved outcomes in esophageal and gastric cancer patients, respectively.
At the 2021 ESMO Annual Meeting, initial data were presented from two clinical trials evaluating sintilimab in combination with chemotherapy against two new cancer indications. Results from the Phase 3 ORIENT-15 and ORIENT-16 trials show that sintilimab plus chemotherapy significantly improved outcomes in esophageal and gastric cancer patients, respectively.
GO Prime with only $1.49 now
LATEST
The Gene & Cell Therapy Landscape: Recent Approvals and Upcoming Therapeutics of Interest
2024-05-06
Exploring Key Areas of RNA Therapeutics Development: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03